We’re In The News

As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.

Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.

Dems’ Platform Highlights ACA, Reproductive Rights

MedPage Today, July 5, 2016. President of the National Center for Health Research called the draft platform “very solid.”

Ikea Is Recalling 1.7 Million More Dressers in China

Fortune, July 12, 2016. The “repair” campaign didn’t mention the word “recall,” and that language choice “reduce[d] the impact” of efforts to “educate and encourage consumers to recognize the need for action when they hear about a recall.

Selling Side Effects: Big Pharma’s Marketing Machine

Drugwatch.com, 2016. New or more expensive drugs are not necessarily better. Ads for drugs are meant to persuade not to educate.

What’s on the Table for the July US-EU Talks Beginning Today?

Who.What.Why., July 11, 2016. EU Trade Commissioner Cecilia Malmström listed several priorities including greater regulatory cooperation for prescription drugs and medical devices. But Diana Zuckerman sees dangers in the EU’s push for more regulatory harmonization for drugs and medical devices.

Congress Shouldn’t Pass the 21st Century Cures Act in a Summer Rush

Health Affairs, July 11, 2016. The full Senate may in the next few days consider companion legislation to the 21st Century Cures Act that passed the House last year. The legislation—currently 19 separate bills—makes substantial changes to the way the Food and Drug Administration (FDA) approves drugs and devices. The legislation, while containing some useful measures, is flawed. Instead of hastily agreeing to it, Congress should postpone consideration until 2017 and attach the best of the 19 bills (see below) to must-pass legislation on FDA funding through industry user fees.